Abstract: The invention relates to antacid preparations comprising the following constituents: (i) an acid-binding active constituent (antacid) or a mixture of such active constituents, (ii) an effervescent mixture that releases CO2, (iii) a polymeric surfactant as foam-forming agent or a mixture of such surfactants, (iv) a swellable and gel-forming polymer or a mixture of such polymers, and (v) optionally conventional auxiliary substances, as well as a process for the production of such antacid preparations. In a particularly preferred embodiment the antacid preparation is formulated in the form of a chewable tablet. The antacid preparations according to the invention are suitable for the symptomatic treatment of duodenal ulcers, gastric ulcers, as well as heartburn and acid-caused gastric disorders such as hyperacidic gastritis.

Abstract: The invention relates to a water-soluble, haemolytically inactive dextran fatty carboxylate with amphiphilic properties made from a dextran with an average molecular weight of 5,000 to 100,000 and a C.sub.10 to C.sub.14 fatty acid, preferably a C.sub.12 fatty acid, wherein the average degree of substitution is between 0.005 and 0.15 and is adjusted, depending on the average molecular weight of the dextran fatty carboxylate and the chain-length of the fatty acid used, in such a way that the dextran fatty carboxylate is soluble in water at room temperature, a process for its preparation and pharmaceutical or cosmetic preparations which contain it as solubilizer.

Abstract: The present invention relates to pharmaceutical formulations which comprise at least one pharmaceutical active compound in combination with a polymer of the general formula I or I', in particular for intravenous administration, ##STR1## in which R.sub.1, R.sub.2, R.sub.5 and R.sub.6 are identical or different and represent hydrogen and a methyl or ethyl group,Q represents a valency, oxygen or an ester or amide bridge and Q' denotes hydrogen if Q represents a valency or oxygen, and is a hydroxyl or amino group if Q represents an ester or amide bridge,x is an integer from 3 to 50, preferably 5 to 40, if Q is a valency or oxygen, and an integer from 3 to 1000, preferably 50 to 100, if Q is an ester or amide function, G.sub.1 and G.sub.2 are a valency, oxygen or an ester or amide group, it being possible for the two groups to be identical or different, n is an integer from 4 to 44, preferably 12 to 16,y is an integer from 2 to 50, preferably 10 to 40, and R.sub.3 is hydrogen or a lower alkyl having 1-6 C atoms.

Abstract: This invention relates to highly active and solid pharmaceutical preparations rapidly releasing the active substance for the treatment of diabetes, particularly: 1. liquid formulations of glibenclamide consisting of 1 part of glibenclamide and 4 to 1500 parts of liquid sugar alcohols such as 70% sorbitol solution or glycol such as propylene glycol, hexylene glycol, di-, tri- or polyethylene glycol having a molecular weight from 76 to 600, optionally 0.5 to 2 moles of an alkaline reacting substance and other drug additives; 2.

Abstract: A nifedipine concentrate stabilized against the influence of light is described, characterized in that it contains nifedipine, polyethylene glycol, from 0.5 to 20% by weight of Vitamin B.sub.2, based on the nifedipine, at least one surface-active agent and optionally conventional carriers. A process for the preparation of the nifedipine concentrate and a medicament containing nifedipine and its use for the production of pharmaceutical preparations are also described.

Abstract: The use of permeation enhancers permits the formulation of transdermal dosage forms for calcium antagonists. These dosage forms are administrable to humans and other mammals, e.g., bovines.

Abstract: The invention relates to a process for the production of pharmaceutical preparations based on 5-aminosalicylic acid in which the 5-aminosalicylic acid is mixed with physiologically and toxicologically acceptable, basic auxiliaries and/or buffer mixtures, which in a 1% aqueous solution give pH-values in the range from 8 to 12, and the mixture obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories, or in which the 5-aminosalicylic acid is mixed with a concentrated aqueous solution of the above-mentioned basic auxiliaries and/or buffer mixtures, the 5-aminosalicylic acid salt formed is precipitated, separated off from the aqueous solution and dried and the salt obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories.

Abstract: Anhydrous emulsion with an oil phase (o) and a hydrophilic phase (p) of water-soluble, but anhydrous liquids, particularly as a filler matrix for medicinal preparations in capsules, which on the one hand does not attack the capsule wall and on the other permits an excellent active agent release.

Abstract: The present invention provides a direct tabletting agent, consisting essentially of lactose and cellulose with a ratio of lactose to cellulose, referred to the weight, of from 95 to 40:5 to 60, the lactose being present partly in crystalline and partly in amorphous form and the cellulose being present as finely-divided powder.The present invention also provides processes for the production of this direct tabletting agent.

Abstract: The invention relates to a process for the production of pharmaceutical preparations based on 5-aminosalicylic acid in which the 5-aminosalicylic acid is mixed with physiologically and toxicologically acceptable, basic auxiliaries and/or buffer mixtures, which in a 1% aqueous solution give pH-values in the range from 8 to 12, and the mixture obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories, or in which the 5-aminosalicylic acid is mixed with a concentrated aqueous solution of the above-mentioned basic auxiliaries and/or buffer mixtures, the 5-aminosalicylic acid salt formed is precipitated, separated off from the aqueous solution and dried and the salt obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories.

Abstract: New foliage fertilizers containing one or more macronutrients and/or one or more micronutrients as well as 10 to 50% by weight (referred to total nutrients) of one or more phospholipids.

Abstract: The invention relates to a process for the production of pharmaceutical preparations based on 5-aminosalicylic acid in which the 5-aminosalicylic acid is mixed with physiologically and toxicologically acceptable, basic auxiliaries and/or buffer mixtures, which in a 1% aqueous solution give pH-values in the range from 8 to 12, and the mixture obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories, or in which the 5-aminosalicylic acid is mixed with a concentrated aqueous solution of the above-mentioned basic auxiliaries and/or buffer mixtures, the 5-aminosalicylic acid salt formed is precipitated, separated off from the aqueous solution and dried and the salt obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories.

Abstract: A process of coating a particulate medicinal agent; comprising the application to said medicinal agent of a liquid composition containing a water-insoluble film-forming agent, a lipophilic solvent, a hydrophilic solvent and water, said liquid composition comprising an emulsion with at least two phases, wherein the liquid components of the liquid composition are removed after application of said liquid composition to said particulate medicinal agent.

Abstract: What are disclosed are methods for making a suspension suitable for use as a coating agent for medicaments by suspending a powder of certain vinyl copolymers in an aqueous solution or suspension of a plasticizer therefor, methods for converting such a suspension of copolymer in plasticizer into a film-forming solution or other extensively homogeneous phase, such suspensions and the film-forming conversion products thereof, and methods for coating medicaments with such suspensions and film-forming conversion products.